the Biomedical Research Network in Cancer (CIBERONC)

2 ARTICLES PUBLISHED IN JoVE

Cancer Research

A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications

Julie Earl¹, Silvia Calabuig-Fariñas¹, María Eugenia Sarasquete¹, Laura Muinelo Romay¹, Sara Lopez-Tarruella¹, Beatriz Bellosillo Paricio¹, Marta Rodríguez¹, Karmele Valencia Leoz¹, Marta Dueñas Porto¹, Noelia Tarazona¹, Javier Hernandez Losa¹, Rodrigo Almeida Toledo¹

¹The Liquid Biopsy and Biomarker Working Module, the Biomedical Research Network in Cancer (CIBERONC)

The liquid biopsy has revolutionized our approach to oncology translational studies, with sample collection, quality, and storage being crucial steps for its successful clinical application. Here we describe a standardized and validated protocol for downstream circulating-free DNA applications that can be applied in most translational research laboratories.

Cancer Research

Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue

Jesús Frutos Díaz-Alejo^*1,2,3,4, Simon April-Monn^*5, Marina Cihova⁶, Verona Buocikova⁶, Jorge Villalón López^1,3, Maria Urbanova⁶, Carmen G. Lechuga⁷, Miroslav Tomas^6,8, Peter Dubovan^6,8, Bárbara Luna Sánchez³, Sonia Camaño Páez³, Alfonso Sanjuanbenito^2,9, Eduardo Lobo⁹, Estefanía Romio de la Heras¹⁰, Carmen Guerra^2,7, Carolina de la Pinta¹¹, Emma Barreto Melian^1,2, Mercedes Rodríguez Garrote^1,2, Alfredo Carrato^1,2,4, Laura Ruiz-Cañas^3,12,13, Bruno Sainz, Jr.^2,3,12,13, Ana Torres³, Bozena Smolkova⁶, Julie Earl^1,2,3

¹Molecular Epidemiology and Predictive Tumor Markers Group, Area 3, Ramón y Cajal Health Research Institute (IRYCIS), ²The Biomedical Research Network in Cancer (CIBERONC), ³Biobank and Biomodels Platform (PT20/0045), ISCIII research and development platforms in biomedicine and health sciences, BioBank Hospital Ramón y Cajal-IRYCIS, Spanish National Biobanks Network (ISCIII Biobank Register No. B.0000678), Ramón y Cajal Health Research Institute (IRYCIS), ⁴Faculty of Medicine, University of Alcalá de Henares, ⁵Institute of Tissue Medicine and Pathology, University of Bern, ⁶Department of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, ⁷Experimental Oncology, Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas (CNIO), ⁸Department of Surgical Oncology, National Cancer Institute, Slovak Medical University, ⁹Pancreatic and Biliopancreatic Surgery Unit, Hospital Universitario Ramón y Cajal, ¹⁰Department of Pathology, Hospital Universitario Ramón y Cajal, ¹¹Department of Radiation Oncology, Hospital Universitario Ramón y Cajal, ¹²Department of Cancer, Instituto de Investigaciones Biomédicas “Alberto Sols” (IIBM), ¹³Cancer Stem Cell and Fibroinflammatory Group, Chronic Diseases and Cancer, Area 3, IRYCIS

Tumor organoids have revolutionized cancer research and the approach to personalized medicine. They represent a clinically relevant tumor model that allows researchers to stay one step ahead of the tumor in the clinic. This protocol establishes tumor organoids from fresh pancreatic tumor tissue samples and patient-derived xenografts of pancreatic adenocarcinoma origin.